Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
Zongwei WangTuo DengXingbo LongXueming LinShulin WuHongbo WangRongbin GeZhenwei ZhangChin-Lee WuMary-Ellen TaplinAria F OlumiPublished in: PloS one (2020)
Our study demonstrate that SRD5A2 methylation in promoter regions, specifically at CpG# -39 to -2, is significantly associated with better survival for CRPC patients treated with ADT. Recognition of epigenetic modifications of SRD5A2 may affect the choices and sequence of available therapies for management of CRPC.